Dr Reddys launches OTC Nicotine Polacrilex Lozenges in US

Hyderabad & Princeton: Dr Reddy's Laboratories Ltd. has announced the launch of Over-the-Counter Nicotine Polacrilex Lozenges, 2 mg and 4 mg, the store brand version of Nicorette® Lozenges in the U.S. market.

The Nicotine Lozenges brands and store brand markets had total U.S. retail sales of approximately $200 million for the most recent 52 weeks ending in May 17, 2020, according to IRI*.

According to Marc Kikuchi, CEO, North America Generics, Dr Reddy's Laboratories, "The launch of Nicotine Polacrilex Lozenges represents our continuing commitment to the OTC category of Smoking Cessation. Nicotine Polacrilex Lozenges are an important addition to our current offering of Nicotine Replacement Therapy including Nicotine Transdermal System Patches, sold as Habitrol® brand and various store brands. This launch truly demonstrates our ability to deliver on more complex dosage forms for the benefit of consumers who wish to quit smoking by reducing withdrawal symptoms, including nicotine cravings."

Dr Reddy's Nicotine Polacrilex Lozenges are available in multiple pack sizes based on consumers' requirements.

Nicorette® is a trademark of GlaxoSmithKline Consumer Healthcare L.P.

Read also: Dr Reddys flags COVID-19 related uncertainties in FY21

Dr Reddy's Laboratories Ltd. is an integrated pharmaceutical company headquartered in Hyderabad, committed to providing affordable and innovative medicines for healthier lives.

Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology.

The Company's markets include – USA, India, Russia & CIS countries, and Europe.

Read also: COVID 19: Dr Reddy's Labs collaborates with FUJIFILM, Global Response Aid for Avigan (favipiravir)